[ANRS HC 02 RIBAVIC: summary and recommandations].
Bani-Sadr
Firouzé
F
Groupe Hospitalier Universitaire Est- Hôpital Tenon-, INSERM U 707, Université Pierre et Marie Curie, Paris, France. firouze.bani-sadr@tnn.ap-hop-paris.fr
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects / Q000379:methods; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005602:France; D015658:HIV Infections / Q000188:drug therapy*; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins; D016896:Treatment Outcome
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins